These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 25394379)

  • 1. MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.
    de Bartolomeis A; Iasevoli F; Tomasetti C; Buonaguro EF
    Mol Neurobiol; 2015 Dec; 52(3):1771-1790. PubMed ID: 25394379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment.
    de Bartolomeis A; Buonaguro EF; Iasevoli F; Tomasetti C
    J Psychopharmacol; 2014 Jun; 28(6):505-26. PubMed ID: 24554693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamatergic postsynaptic density protein dysfunctions in synaptic plasticity and dendritic spines morphology: relevance to schizophrenia and other behavioral disorders pathophysiology, and implications for novel therapeutic approaches.
    de Bartolomeis A; Latte G; Tomasetti C; Iasevoli F
    Mol Neurobiol; 2014 Feb; 49(1):484-511. PubMed ID: 23999870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins.
    de Bartolomeis A; Tomasetti C
    Mol Neurobiol; 2012 Oct; 46(2):275-96. PubMed ID: 22763587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin-glutamate and serotonin-dopamine reciprocal interactions as putative molecular targets for novel antipsychotic treatments: from receptor heterodimers to postsynaptic scaffolding and effector proteins.
    de Bartolomeis A; Buonaguro EF; Iasevoli F
    Psychopharmacology (Berl); 2013 Jan; 225(1):1-19. PubMed ID: 23179966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dysregulated Signaling at Postsynaptic Density: A Systematic Review and Translational Appraisal for the Pathophysiology, Clinics, and Antipsychotics' Treatment of Schizophrenia.
    de Bartolomeis A; Vellucci L; De Simone G; Mazza B; Barone A; Ciccarelli M
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions.
    Tomasetti C; Iasevoli F; Buonaguro EF; De Berardis D; Fornaro M; Fiengo AL; Martinotti G; Orsolini L; Valchera A; Di Giannantonio M; de Bartolomeis A
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review.
    de Bartolomeis A; Barone A; Vellucci L; Mazza B; Austin MC; Iasevoli F; Ciccarelli M
    Mol Neurobiol; 2022 Oct; 59(10):6460-6501. PubMed ID: 35963926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia.
    Iasevoli F; Buonaguro EF; Sarappa C; Marmo F; Latte G; Rossi R; Eramo A; Tomasetti C; de Bartolomeis A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Oct; 54():299-314. PubMed ID: 25025505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutamate and dopamine in schizophrenia: an update for the 21st century.
    Howes O; McCutcheon R; Stone J
    J Psychopharmacol; 2015 Feb; 29(2):97-115. PubMed ID: 25586400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia.
    de Bartolomeis A; Avagliano C; Vellucci L; D'Ambrosio L; Manchia M; D'Urso G; Buonaguro EF; Iasevoli F
    Neurosci Biobehav Rev; 2019 Dec; 107():795-827. PubMed ID: 31461641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.
    de Bartolomeis A; Fiore G; Iasevoli F
    Curr Pharm Des; 2005; 11(27):3561-94. PubMed ID: 16248808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment.
    Iasevoli F; Tomasetti C; Buonaguro EF; de Bartolomeis A
    Curr Neuropharmacol; 2014 May; 12(3):219-38. PubMed ID: 24851087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutamatergic agents for schizophrenia: current evidence and perspectives.
    Zink M; Correll CU
    Expert Rev Clin Pharmacol; 2015 May; 8(3):335-52. PubMed ID: 25916667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
    de Bartolomeis A; Ciccarelli M; De Simone G; Mazza B; Barone A; Vellucci L
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia.
    de Bartolomeis A; Manchia M; Marmo F; Vellucci L; Iasevoli F; Barone A
    Front Psychiatry; 2020; 11():369. PubMed ID: 32477178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction between N-methyl-D-aspartic acid receptors and D1 dopamine receptors: an important mechanism for brain plasticity.
    Scott L; Aperia A
    Neuroscience; 2009 Jan; 158(1):62-6. PubMed ID: 19000746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
    de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
    Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats.
    de Bartolomeis A; Marmo F; Buonaguro EF; Latte G; Tomasetti C; Iasevoli F
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():24-38. PubMed ID: 27177972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications.
    Carlsson A; Hansson LO; Waters N; Carlsson ML
    Life Sci; 1997; 61(2):75-94. PubMed ID: 9217267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.